Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma

<div>External datasets were used to validate the robustness of the prognostic model. The OS in the validation dataset of the GEO database: GSE30219 dataset (a), GSE37745 dataset (b), and GSE50081 dataset (c). The ROC curves of OS in the validation dataset of the GEO database: GSE30219 dataset (d), GSE37745 dataset (e), and GSE50081 dataset (f).</div>

Analytical Cellular Pathology

fig8

Figure 8

Figure 8: Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma 

Figure 8 | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma 